Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02615184 · ClinicalTrials.gov registry record · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
A Phase 2 study of Erosive Esophagitis, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT02615184 is a Phase 2 study of Erosive Esophagitis that is actively recruiting participants, run by Takeda. The registered enrollment target is 76 participants, below the 198-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT02615184, a Phase 2 study of Erosive Esophagitis, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of GERD include pain in the stomach or throat, difficulty eating, and throwing up. Sometimes GERD damages the lining of the esophagus, creating breaks. This is called erosive esophagitis (EE). Dexlansoprazole is a type of medicine that helps lower the amount of acid made in the stomach. It has been shown to heal EE and maintain (keep) healing of EE in adults and teenagers. This study is being done to find out if dexlansoprazole can also heal EE and maintain the healing of EE in children.
Conditions Studied
Interventions
- DRUG Dexlansoprazole
Study Locations (20)
Other
- Hospital Universitario San Ignacio - Bogotá
- Fundacion Valle del Lili - Cali
- Centro Medico Imbanaco de Cali S.A - Cali
- El Cielo Medical Center - Puebla City
Tennessee
- GI for Kids - Knoxville
- Vanderbilt University Medical Center - Nashville
Alabama
- University of South Alabama - Mobile
California
- University of California San Francisco - San Francisco
Florida
- D&H National Research Centers - Miami
Georgia
- Children's Center for Digestive Health Care, LLC - Atlanta
Mississippi
- Gastrointestinal Associates, PA - Flowood
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02615184
The ClinicalTrials.gov registry entry for NCT02615184 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (62% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Erosive Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which Dexlansoprazole is the first listed.
NCT02615184 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Tennessee, Alabama.
Frequently Asked Questions
What is clinical trial NCT02615184 about?
NCT02615184 is a clinical study titled "A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old". Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus ...
What is the current status of trial NCT02615184?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2023-05-23. Estimated completion is 2027-10-31.
What conditions does trial NCT02615184 study?
This clinical trial studies the following conditions: Erosive Esophagitis.
What interventions are being tested in trial NCT02615184?
The interventions under investigation include: Dexlansoprazole (DRUG).
Who is sponsoring clinical trial NCT02615184?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02615184 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erosive Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
COMPLETED · Phase 2
-
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
COMPLETED · Phase 2
-
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
RECRUITING · Phase 3
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
-
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
COMPLETED · Phase 4
-
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.